Study identifies potential drug for treatment of debilitating inherited neurological disease

March 15, 2018, St. Jude Children's Research Hospital

St. Jude Children's Research Hospital scientists have demonstrated in mouse studies that the neurological disease spinal bulbar muscular atrophy (SBMA) can be successfully treated with drugs. The finding paves the way for clinical trials for treating the disease and even preventing its progression in individuals who have inherited the disease mutation.

The researchers, led by J. Paul Taylor, M.D., Ph.D., a Howard Hughes Medical Institute (HHMI) investigator and chair of the St. Jude Department of Cell and Molecular Biology, published their findings March 5 in the journal Nature Medicine.

SBMA, or Kennedy's disease, affects only men, causing loss of muscle-controlling motor neurons, leading to muscle wasting and impaired ability to talk and swallow. As the disorder progresses, men with the disorder often become wheelchair bound and require help with such tasks as eating.

The disease is caused by a mutation in the androgen receptor, which is activated by the male hormone testosterone. The mutation causes a malfunction of the receptor that triggers toxicity in motor neurons, killing them. The mutation also causes the receptor to become less sensitive to testosterone, which can lead to feminization, testicular atrophy and infertility. SBMA affects about 1 in every 40,000 men worldwide, a number that is likely underestimated because of its misdiagnosis as another disorder.

Taylor and his colleagues were led to seek drugs to treat SBMA because of findings from a previous study in his laboratory. The study pinpointed a molecular niche in the mutant androgen receptor protein that appeared to be a key to driving SBMA symptoms. However, that niche did not seem to be essential to the normal function of the androgen receptor. The study started with fruit flies genetically engineered to have the human androgen receptor, giving the scientists a living "test tube" to explore the effects of mutating the receptor.

"This identification of a small patch of this protein that appeared to be functionally important for driving the disease, but is not essential for most androgen receptor functions, gave us a potential target," Taylor said.

Pharmaceutical companies have been developing drugs to target this small patch, called the "activator function-2" or "AF2" domain. The companies were testing the drugs as possible treatments for prostate cancer, which also involves the . Taylor obtained a collection of the test drugs to evaluate for use with SBMA.

Using the genetically engineered flies, the researchers identified two drugs—whose long chemical names are abbreviated TA and MEPB—that alleviated SBMA symptoms. Then, using mice, the scientists determined that MEPB more effectively reached target tissues in the brain and spinal cord.

For their trials of TA and MEPB as potential SBMA treatments, the researchers developed a new genetically engineered mouse model to more accurately mimic the mutation found in men with SBMA. The transgenic mice showed many of the symptoms of humans with the disease.

Researchers found that MEPB effectively alleviated symptoms of SBMA in the mice. "Treating the mice with MEPB forestalled muscle atrophy and prevented loss of their , with recovery of their testicles to normal size," Taylor said. "The treatment also protected their ability to walk and their muscle strength and endurance."

Taylor said drugs to treat SBMA would be useful in restoring function in adult men with the disease and preventing it in children who inherit the mutation for SBMA.

"At this point, while we do have an accurate genetic test for the disease, we must warn people with a family history that if that test reveals the , we do not have a therapy available," he said. "However, if we did have a drug therapy, we could start treating children before puberty, when the disease manifests, so they either don't get the , or we can at least dramatically mitigate it."

Taylor is seeking to partner with pharmaceutical companies to further test the drugs as treatments for SBMA. "Our proof-of-concept study demonstrates that this class of compounds can be effective," he said. "And we can offer predictive cell culture and fly models that can quickly identify the most viable candidates for further development and clinical trials."

Explore further: Mutant protein in muscle linked to neuromuscular disorder

More information: Nisha M Badders et al. Selective modulation of the androgen receptor AF2 domain rescues degeneration in spinal bulbar muscular atrophy, Nature Medicine (2018). DOI: 10.1038/nm.4500

Related Stories

Mutant protein in muscle linked to neuromuscular disorder

April 16, 2014
Sometimes known as Kennedy's disease, spinal and bulbar muscular atrophy (SBMA) is a rare inherited neuromuscular disorder characterized by slowly progressive muscle weakness and atrophy. Researchers have long considered ...

Scientists put some muscle behind their research

May 6, 2016
Michigan State University researchers used an old-fashioned neurobiology technique to explore new avenues for treatments to reverse a late-onset neurodegenerative disease that robs men of the capacity to walk, run, chew and ...

Target identified for rare inherited neurological disease in men

August 10, 2014
Researchers at University of California, San Diego School of Medicine have identified the mechanism by which a rare, inherited neurodegenerative disease causes often crippling muscle weakness in men, in addition to reduced ...

Having Huntington's disease or other 'polyQ' diseases protects against cancer, suggesting common genetic mechanism

April 11, 2012
Having Huntington's disease or other diseases known as polyglutamine (polyQ) diseases reduces a person's risk of getting cancer, suggesting a common genetic mechanism, concludes an Article published Online First by The Lancet ...

Recommended for you

Gene plays critical role in noise-induced deafness

October 19, 2018
In experiments using mice, a team of UC San Francisco researchers has discovered a gene that plays an essential role in noise-induced deafness. Remarkably, by administering an experimental chemical—identified in a separate ...

Functional engineered oesophagus could pave way for clinical trials 

October 18, 2018
The world's first functional oesophagus engineered from stem cells has been grown and successfully transplanted into mice, as part of a pioneering new study led by UCL.

New findings cast light on lymphatic system, key player in human health

October 16, 2018
Scientists at the Oklahoma Medical Research Foundation have broken new ground in understanding how the lymphatic system works, potentially opening the door for future therapies.

New model suggests cuffless, non-invasive blood pressure monitoring possible using pulse waves

October 16, 2018
A large team of researchers from several institutions in China and the U.S. has developed a model that suggests it should be possible to create a cuffless, non-invasive blood pressure monitor based on measuring pulse waves. ...

Age-related increase in estrogen may cause common men's hernia

October 16, 2018
An age-related increase in estrogen may be the culprit behind inguinal hernias, a condition common among elderly men that often requires corrective surgery, according to a Northwestern Medicine study was published Oct. 15 ...

Income and wealth affect the mental health of Australians, study shows

October 16, 2018
Australians who have higher incomes and greater wealth are more likely to experience better mental health throughout their lives, new research led by the Bankwest Curtin Economics Centre has found.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.